Literature DB >> 26928187

Management of patients with complex regional pain syndrome type I.

D Gatti1, M Rossini2, S Adami2.   

Abstract

Complex regional pain syndrome type I (CRPS-I) includes different conditions characterized by regional pain and sensory, motor, sudomotor, vasomotor, and/or trophic findings, affecting a peripheral limb usually after a noxious event, such as a trauma or surgery. The pathophysiology is still poorly understood. Limited data are available on the incidence of CRPS-I, and the disease is underestimated and under-diagnosed. The disease shows a female preponderance approximately 3:1 with a peak age of incidence around the 5th and 6th decade. The available diagnostic criteria for CRPS-I rely on clinical criteria that are unfortunately focused on the signs and symptoms of the chronic and late disease, while little emphasis is given to the typical imaging (X-rays, bone scintigraphy, MRI) findings of the early phase. Over the last decades, several therapies have been proposed but the few studies available are often too small to be conclusive and rarely evolved to randomized controlled trials (RCTs). On the basis of the results of a few RCTs, only short courses of high bisphosphonate doses appear to provide substantial benefits. The best results are seen in patients in the early phase of the disease, often with the persistent remission or complete healing of the conditions. Since the only accredited mechanism of action of bisphosphonates is the suppression of osteoclastic bone resorption, it is likely the initial dramatic bone loss plays a role in the maintenance and evolution of CRPS-I. Short courses of high doses of bisphosphonates should be considered the treatment of choice for patients with CRPS-I.

Entities:  

Keywords:  Bisphosphonates; Complex regional pain syndrome type I; Neridronate

Mesh:

Substances:

Year:  2016        PMID: 26928187     DOI: 10.1007/s00198-016-3531-9

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  51 in total

1.  Bisphosphonate therapy of reflex sympathetic dystrophy syndrome.

Authors:  S Adami; V Fossaluzza; D Gatti; E Fracassi; V Braga
Journal:  Ann Rheum Dis       Date:  1997-03       Impact factor: 19.103

2.  Long-term effects of neridronate and its discontinuation in patients with primary hyperparathyroidism.

Authors:  Maurizio Rossini; Ombretta Viapiana; Banu Kalpakcioglu; Rajoo Dhangana; Davide Gatti; Vania Braga; Elena Fracassi; Silvano Adami
Journal:  Calcif Tissue Int       Date:  2011-05-13       Impact factor: 4.333

3.  Peripheral nerve pathology in patients with severely affected complex regional pain syndrome type I.

Authors:  Jan H B Geertzen; Marlies I Bodde; Jan J A van den Dungen; Pieter U Dijkstra; Wilfred F A den Dunnen
Journal:  Int J Rehabil Res       Date:  2015-06       Impact factor: 1.479

4.  Epidemiology of complex regional pain syndrome: a retrospective chart review of 134 patients.

Authors:  G Allen; B S Galer; L Schwartz
Journal:  Pain       Date:  1999-04       Impact factor: 6.961

5.  Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.

Authors:  Davide Gatti; Franco Antoniazzi; Rosangela Prizzi; Vania Braga; Maurizio Rossini; Luciano Tatò; Ombretta Viapiana; Silvano Adami
Journal:  J Bone Miner Res       Date:  2004-12-20       Impact factor: 6.741

6.  Comparison of prednisolone with piroxicam in complex regional pain syndrome following stroke: a randomized controlled trial.

Authors:  J Kalita; A Vajpayee; U K Misra
Journal:  QJM       Date:  2006-01-20

7.  Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity.

Authors:  Daniel-Henri Manicourt; Jean-Pierre Brasseur; Yves Boutsen; Geneviève Depreseux; Jean-Pierre Devogelaer
Journal:  Arthritis Rheum       Date:  2004-11

8.  Inflammatory mediators are altered in the acute phase of posttraumatic complex regional pain syndrome.

Authors:  Christian Schinkel; Andreas Gaertner; Johannes Zaspel; Siegfried Zedler; Eugen Faist; Matthias Schuermann
Journal:  Clin J Pain       Date:  2006 Mar-Apr       Impact factor: 3.442

9.  Validation of proposed diagnostic criteria (the "Budapest Criteria") for Complex Regional Pain Syndrome.

Authors:  R Norman Harden; Stephen Bruehl; Roberto S G M Perez; Frank Birklein; Johan Marinus; Christian Maihofner; Timothy Lubenow; Asokumar Buvanendran; Sean Mackey; Joseph Graciosa; Mila Mogilevski; Christopher Ramsden; Melissa Chont; Jean-Jacques Vatine
Journal:  Pain       Date:  2010-05-20       Impact factor: 6.961

10.  Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.

Authors:  Daniela Merlotti; Luigi Gennari; Giuseppe Martini; Fabrizio Valleggi; Vincenzo De Paola; Annalisa Avanzati; Ranuccio Nuti
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

View more
  4 in total

1.  Evaluation of bone microstructure in CRPS-affected upper limbs by HR-pQCT.

Authors:  Haider Mussawy; Tobias Schmidt; Tim Rolvien; Wolfgang Rüther; Michael Amling
Journal:  Clin Cases Miner Bone Metab       Date:  2017-05-30

2.  Bone microstructure is significantly altered in CRPS-affected distal tibiae as detected by HR-pQCT: a retrospective cross-sectional study.

Authors:  Nicola Oehler; Tim Rolvien; Tobias Schmidt; Sebastian Butscheidt; Ralf Oheim; Florian Barvencik; Haider Mussawy
Journal:  J Bone Miner Metab       Date:  2018-11-21       Impact factor: 2.626

Review 3.  Usefulness of bone scintigraphy for the diagnosis of Complex Regional Pain Syndrome 1: A systematic review and Bayesian meta-analysis.

Authors:  Maria M Wertli; Florian Brunner; Johann Steurer; Ulrike Held
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

Review 4.  Molecular Aspects of Regional Pain Syndrome.

Authors:  Manuela Baronio; Hajra Sadia; Stefano Paolacci; Domenico Prestamburgo; Danilo Miotti; Vittorio A Guardamagna; Giuseppe Natalini; Stephanie G B Sullivan; Matteo Bertelli
Journal:  Pain Res Manag       Date:  2020-04-11       Impact factor: 3.037

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.